D. E. Shaw & Co., Inc. Lineage Cell Therapeutics, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LCTX
# of Institutions
122Shares Held
94.3MCall Options Held
63.8KPut Options Held
1K-
Broadwood Capital Inc New York, NY41.7MShares$35.8 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$8.22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.6MShares$7.4 Million0.0% of portfolio
-
Defender Capital, Llc.5MShares$4.3 Million1.58% of portfolio
-
Logos Global Management LP San Francisco, CA5MShares$4.3 Million0.6% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $146M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...